Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.45 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.36 |
| ▸ | KIT | P10721 | 4/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021244 | 0.91 | ORAI1 (0.41) | CYP17A1ORAI1PTGS2 | |
| SCHEMBL15020511 | 0.89 | ORAI1 (0.41) | CYP17A1ORAI1PTGS2PIK3CGKIT | |
| SCHEMBL15020682 | 0.81 | BRD4 (0.50) | ORAI1PIK3CGKITBRD4 | |
| SCHEMBL15020509 | 0.80 | ORAI1 (0.72) | ORAI1PIK3CGKITBRD4 | |
| SCHEMBL1460211 | 0.76 | CLK2 (0.47) | PTGS2KIT | |
| SCHEMBL15060068 | 0.76 | KIT (0.34) | ORAI1PTGS2KIT | |
| SCHEMBL15750989 | 0.72 | ORAI1 (0.59) | CYP17A1ORAI1PIK3CA | |
| SCHEMBL15036358 | 0.71 | RIPK1 (0.37) | CYP17A1ORAI1KITCDK9 | |
| SCHEMBL15020681 | 0.70 | ULK1 (0.36) | ORAI1KITPIK3CAATRCCNT1 | |
| SCHEMBL15751017 | 0.70 | ORAI1 (0.73) | ORAI1PIK3CGKITBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | claimed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | claimed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | CYP17A1 2665/4885ORAI1 1/4885PTGS2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.